Coronary flow reserve: A new target for treating hypertension

Hypertension Research

Volumn 32, Issue 4, 2009, Pages 316-

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Echarri, Rocio ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; NIFEDIPINE; PLACEBO; TELMISARTAN;

BLOOD PRESSURE REGULATION; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY FLOW RESERVE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LETTER; MICROCIRCULATION; MORTALITY; TREATMENT DURATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY CIRCULATION; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 77950506727     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.15     Document Type: Letter

References (7)

1. Palombo C, Kozakova M, Magagna A, Bigalli G, Morizzo C, Ghiadoni L, Virdis A, Emdin M, Taddei S, L'Abbate A, Salvetti A. Early impairment of coronary flow reserve and increase in minimum coronary resistance in bordeline hypertensive patients. J Hypertens 2000; 18: 453-459.
2. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15: 43-51.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
4. Hinoi T, Tomohiro Y, Kajiwara S, Matsuo S, Fujimoto Y, Yamamoto S, Shichijo T, Ono T. Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy. Hypertens Res 2008; 31: 615-622.
5. Schiffrin EL, Park JB, Intentan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan. Circulation 2000; 101: 1653-1659.
6. Tomás JP, Moya JL, Barrios V, Campuzano R, Guzman G, Megías A, Ruiz-Leria S, Catalán P, Marfil T, Tarancón B, Muriel A, García-Lledó A. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24: 2109-2114.
7. Barrios V, Escobar C. Antihypertensive agents: are all of them equal? South Med J 2008; e-pub ahead of print 9 July 2008.